Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial

Trial Profile

RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms RIBS-IV
  • Most Recent Events

    • 01 May 2021 Results of pooled analysis from ribs IV and V studies assessing influence of neoatherosclerosis on the prognosis and response to treatment of patients with SR published in the Revista Espanola de Cardiologia
    • 05 Jan 2017 Results (n=249) of pooled analysis of RIBS IV and RIBS V studies assessing the safety and efficacy of DEB in patients with ISR, published in the American Journal of Cardiology
    • 08 Dec 2015 Results (pooled analysis of RIBS IV and RIBS V trials) published in the American Journal of Cardiology (n = 442).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top